The potential for drug interactions with statin therapy in Ireland

被引：32

作者：

Heerey A. ^{[1
]}

Barry M. ^{[1
]}

Ryan M. ^{[1
]}

Kelly A. ^{[1
]}

机构：

[1] Department of Pharmacology and Therapeutics, University of Dublin, Trinity College, Dublin

来源：

Irish Journal of Medical Science | 2000年 / 169卷 / 3期

关键词：

Statin; Simvastatin; Atorvastatin; Itraconazole; Pravastatin;

D O I：

10.1007/BF03167690

中图分类号：

学科分类号：

摘要：

Background. Seven per cent of acute hospital admissions result from adverse drug reactions, of which 25% are due to drug interactions. Adverse effects of statin drugs occur in 3% of patients, mainly due to co-prescribing with other lipid-lowering agents or agents that alter their metabolism. Aim. The aim of this study was to investigate co-prescribing of the frequently-used statin medications with interacting drugs. Methods. Data from the General Medical Services (GMS) scheme of the Eastern Health Board from January to December 1998 were used in this study. Using the coding index for statins, co-prescribing was identified when concomitant medications were administered under the same GMS claim number. Results. Of 7,602 patients prescribed statins, co-prescribing of simvastatin, atorvastatin and fluvastatin with competing substrates or inhibitors of their metabolism occurred in 32, 26 and 13.4% of prescriptions issued. Thirty-four per cent of patients on simvastatin, 28% on atorvastatin and 16% on fluvastatin were prescribed medications with drug interaction potential. Conclusion. Co-prescribing of statins with competing substrates or inhibitors of their metabolism occurred in up to one-third of prescriptions issued. When statins are co-prescribed with recognised inhibitors of drug metabolism, pravastatin, which does not undergo significant hepatic metabolism, is the statin of choice.

引用

页码：176 / 179

页数：3

共 20 条

[1]

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)

[2]

Sacks F.M., Pfeffer M.A., Moye L.A., Et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, pp. 1001-1009, (1996)

[3]

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, pp. 1349-1357, (1998)

[4]

Shepherd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, pp. 1301-1307, (1995)

[5]

Downs J.R., Clearfield M., Weis S., Et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, J Am Med Assoc, 279, pp. 1615-1622, (1998)

[6]

Barry M., Heerey A., Sheehan O., Et al., Pharmacoeconomics of lipid lowering therapy in Ireland, Ir Med J, 92, pp. 430-432, (1999)

[7]

Christians U., Jacobsen W., Floren L.C., Metabolism and drug interactions of 3′-hydroxy-3′-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?, Pharmacol Ther, 80, pp. 1-34, (1998)

[8]

Pitt B., Waters D., Brown W.V., Et al., Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease, N Engl J Med, 341, pp. 70-76, (1999)

[9]

Lennernas H., Fager G., Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences, Clin Pharmacokinet, 32, pp. 403-425, (1997)

[10]

Bottorff M., Fire and forget?' - Pharmacological considerations in coronary care, Atherosclerosis, 147, pp. 23-30, (1999)

← 1 2 →